Rossari Biotech Limited's material subsidiary, Unitop Chemicals Private Limited, has successfully acquired rights to leasehold land in the Gujarat Industrial Development Corporation (GIDC) industrial estate. This move supports the company's expansion plans in the industrial chemicals sector.

Key Details of the Land Transfer

Implications for Rossari Biotech

The transfer of land rights to Unitop Chemicals Private Limited marks a step in Rossari Biotech's expansion. This move may strengthen the subsidiary's operational capabilities in the industrial chemicals sector, potentially leading to increased production capacity and market presence.

Background

Rossari Biotech Limited, a company known for its presence in the specialty chemicals sector, has been focusing on expanding its footprint in various industrial segments. The acquisition of land rights by its material subsidiary aligns with this strategy, indicating the company's efforts to enhance its manufacturing capabilities.

Conclusion

This land rights transfer represents a development for Rossari Biotech and its subsidiary, Unitop Chemicals. As the industrial chemicals sector continues to evolve, such expansions could play a role in maintaining competitiveness and driving growth in the market.

Rossari Biotech Limited, a leading specialty chemicals manufacturer, has reported a robust 18% year-over-year revenue growth for the second quarter of fiscal year 2026, reaching Rs. 586.1 crore. The company's performance was primarily driven by volume expansion across all three of its core business segments.

Key Financial Highlights

• Revenue: Rs. 586.10 crore (18% YoY growth)
• EBITDA: Rs. 71.90 crore
• EBITDA Margin: 12.3% (compared to 13.2% in Q2 FY25)
• Core EBITDA Margin (excluding institutional and B2C verticals): Approximately 15%

Segment-wise Performance

Export Performance

• Q2 Export Growth: 36% YoY
• H1 Export Growth: 27% YoY
• Export Contribution: 28% of total revenues

Operational Highlights

• Commissioned additional capacity of 20,000 metric tons per annum at Dahej facility
• Added 15,000 metric tons per annum of ethoxylation capacity at Unitop (first phase of planned 30,000 MTPA expansion)

Market Challenges and Outlook

The company faces pricing pressures due to tariff uncertainties affecting textile exports to the US. Management expects margin levels to remain similar in H2 FY26, with the core business maintaining 14-16% EBITDA margins.

Working Capital

Working capital increased to 102 days from 95 days in March due to stretched receivables and strategic inventory stocking.

Edward Menezes, Promoter and Executive Chairman of Rossari Biotech, commented on the company's innovation efforts: "Over the past six to nine months, our teams have developed new products, both in Ethylene Oxide-based and non-EO-based, guided by green chemistry principles to deliver sustainable, scalable, and customized solutions for customers across industries."

Sunil Chari, Promoter and Managing Director, highlighted the export performance: "Our international business delivered robust growth with exports rising 36% YoY in Q2 and 27% in H1. This growth was driven by improved traction with key customers, higher wallet share with strategic partners, and deeper penetration in both existing and new geographies."

The company's management remains optimistic about sustaining healthy growth momentum in the coming fiscal year, supported by new capacities coming on stream and a robust pipeline of new products developed through focused R&D efforts.

Despite the challenges posed by global tariff uncertainties, Rossari Biotech's diversified product portfolio and expanding international presence have helped the company maintain its growth trajectory. The company's focus on innovation and capacity expansion positions it well to capitalize on emerging opportunities in the specialty chemicals sector.